Key Takeaways
- KALA BIO revealed plans to deploy its inaugural commercial AI solution within approximately 14 days
- The firm aims to become the “Palantir for biotech” in a healthcare AI market projected at $180 billion
- Researgency.ai will deliver AI-powered agents tailored for pharmaceutical and biotech operations
- Pre-market trading Wednesday saw KALA shares climb 69.68%, following Tuesday’s 12.82% increase
- Trading activity reached 51 million shares, dwarfing the three-month daily average of approximately 1.94 million
Shares of KALA BIO climbed sharply during Wednesday’s pre-market session following the clinical-stage biotechnology firm’s announcement of an imminent commercial AI product launch scheduled for mid-March.
Pre-market trading showed shares gaining 69.68% ahead of the opening bell, building on Tuesday’s 12.82% advance. Trading activity surged past 51 million shares, vastly exceeding the three-month daily average of around 1.94 million.
$KALA < $.50c – Kala Bio
🔹Launches a Revolution for Biotech
🔹First AI Agent Deploying in 14 Days
🔹Platform rebrand complete and https://t.co/u7uaqZThkx reported live for enterprise deployment
🔹Company retains a drug pipeline with Orphan Drug and Fast Track designations… pic.twitter.com/XqCPhrULlS— John Zidar aka/ Stock Wizard (@JohnZidar) March 11, 2026
The firm is introducing Researgency.ai, a specialized platform designed to deliver AI agents serving biotech and pharmaceutical enterprises. KALA positions its ambition as becoming the “Palantir for biotech,” referencing Palantir’s market capitalization exceeding $250 billion as a benchmark.
CEO Avi Minkowitz stated directly: “Our first agent ships in 14 days, and our team is fired up.”
Development of the inaugural custom agent involves collaboration with Younet’s AI engineering division, targeting late March delivery. The Researgency.ai platform has gone live and accepts enterprise customer access.
Platform Capabilities
These AI agents target labor-intensive, critical-path activities throughout drug development cycles. Functions encompass research tracking, clinical documentation, regulatory adherence, safety data reporting, and commercial readiness preparation.
According to KALA, these agents deliver superior speed, cost efficiency, and accuracy compared to manual human execution of comparable tasks. The platform architecture emphasizes secure operations meeting pharmaceutical industry compliance requirements.
KALA referenced industry forecasts estimating the global healthcare AI sector will surpass $180 billion by 2030. The company currently carries a market capitalization of merely $8.3 million, with shares trading at $0.29.
Year-to-date performance shows a 47.21% decline, while the trailing 12-month period reflects a 95.78% drop. Wednesday’s pre-market rally still leaves shares trading near all-time lows.
Parallel Operations and Balance Sheet Challenges
KALA BIO maintains a dual-focus operating model. The company continues advancing its biologics development pipeline, featuring FDA Orphan Drug and Fast Track designated candidates derived from its mesenchymal stem cell secretome technology platform.
The strategic pivot toward AI arrives during a period of significant financial constraints. The company’s current ratio registers at 0.75, indicating liquid assets fall short of near-term liabilities.
Earlier in 2025, KALA reached a settlement agreement with Oxford Finance. The resolution involved a $2 million payment to address approximately $10.6 million in outstanding obligations stemming from a prior lending arrangement.
The firm recently ended its relationship with auditing firm Deloitte & Touche LLP. A successor audit firm has yet to be announced.
KALA has withheld disclosure regarding Researgency.ai platform pricing structures, the specific operational workflow the inaugural agent addresses, or concrete information about secured customer agreements.
Management indicated comprehensive details covering the first agent will be shared post-launch, encompassing the targeted workflow application and performance evaluation methodology.
